Life Sciences Archives - EverGlade Consulting

Life Sciences

3D rendering of Lymphocytes

DoD Seeks Host-Directed Therapeutics to Counter Emerging Biological Threats

Leave a Comment / All Posts, JPEO, Life Sciences / By

A New Direction: Host-Directed, Not Pathogen-Specific Unlike traditional antivirals or antibiotics, host-directed therapeutics (HDTs) focus on modulating the patient’s immune response rather than targeting a specific pathogen. This “threat-agnostic” approach is especially promising in an era marked by evolving biological agents and unpredictable infectious threats. The DoD is particularly interested in repurposed FDA-approved therapeutics or […]

DoD Seeks Host-Directed Therapeutics to Counter Emerging Biological Threats Read More »

Chemical Threat Readiness

Advancing Chemical Threat Readiness: The MCDC’s New Call for Prototypes

Leave a Comment / DTRA, Life Sciences / By

Advancing Chemical Threat Readiness: The MCDC’s New Call for Prototypes April 2025 marks another pivotal moment for U.S. defense readiness in chemical and biological threat detection. Through the Medical CBRN Defense Consortium (MCDC), the Army Contracting Command has issued Solicitation RPP-25-04 seeking Enhanced White Papers for a groundbreaking prototype: the Assay Expansion for Chemical Diagnostic

Advancing Chemical Threat Readiness: The MCDC’s New Call for Prototypes Read More »

immunoassay IEID Lab Solicitation

BARDA’s Central IEID Lab Solicitation: Strengthening Immunoassay Readiness for Pandemic Threats

Leave a Comment / All Posts, BARDA, Life Sciences / By

Why It Matters The rise of highly pathogenic avian influenza (HPAI) strains like H5N1, their spread to livestock, and increasing zoonotic infections in the U.S. has underscored the need for rapid, accurate immune assay infrastructure. BARDA’s RRPV initiative calls for laboratories with existing capabilities to function as a central immunoassay laboratory and perform quality-assured immunoassays

BARDA’s Central IEID Lab Solicitation: Strengthening Immunoassay Readiness for Pandemic Threats Read More »

PROSPR program

Proactive Solutions for Prolonging Resilience Opportunity Announcement

Leave a Comment / All Posts, ARPA-H, Life Sciences / By

The Foci of PROSPR ARPA-H-SOL-25-125, PROSPR The PROSPR solicitation outlines a comprehensive, multi-year program structured around the development, validation, and deployment of novel health technologies. The program is divided into three primary technical areas (TAs), each addressing a critical component of healthspan extension: TA1 focuses on developing a PROSPR Intrinsic Capacity (IC) score that quantifies

Proactive Solutions for Prolonging Resilience Opportunity Announcement Read More »

organophosphorus nerve agents

Project UPREG

Leave a Comment / All Posts, DTRA, Life Sciences / By

Project UPREG: DTRA’s Push for Enhanced Protection Against Nerve Agents The Defense Threat Reduction Agency’s (DTRA) Chemical and Biological Technologies Department, in its role as the Joint Science and Technology Office (JSTO), has launched Project UPREG, a bold initiative to develop next-generation medical countermeasures against organophosphorus nerve agents (OPNAs). These highly toxic compounds pose a

Project UPREG Read More »

BARDA merge with ARPA-H

What the HHS Reorganization Means for BARDA, Contractors, and the Office of Healthy Futures

Leave a Comment / All Posts, BARDA, Life Sciences / By

The U.S. Department of Health and Human Services (HHS) is undergoing one of the most significant structural transformations in its history. This realignment affects not only public health preparedness and biomedical innovation but also the broader operational framework, including funding mechanisms, programmatic leadership, and cross-agency coordination structures that supports millions of Americans across health care,

What the HHS Reorganization Means for BARDA, Contractors, and the Office of Healthy Futures Read More »

ARPA-H_Mission Office Innovative Solutions Openings (ISO)

ARPA-H Mission Office Innovative Solutions Openings (ISOs)

Leave a Comment / All Posts, ARPA-H, Life Sciences / By

Overview The Advanced Research Projects Agency for Health (ARPA-H) is dedicated to accelerating transformative health solutions by tackling some of the most pressing challenges in biomedical and healthcare innovation. As part of this mission, ARPA-H has launched Mission Office Innovative Solutions Openings (ISOs) that promote the development of health technologies that lie outside of the

ARPA-H Mission Office Innovative Solutions Openings (ISOs) Read More »

NIH resume issuing grants

NIH Admits Funding Freeze Was Illegal, Resumes Issuing Grants

Leave a Comment / All Posts, Life Sciences, NIH / By

Overview In a major development for the biomedical research community, the National Institutes of Health (NIH) has officially acknowledged that its recent funding freeze was unlawful and has announced the resumption of grant distributions. This decision follows weeks of controversy and legal challenges, during which research institutions, universities, and lawmakers criticized the abrupt halt in

NIH Admits Funding Freeze Was Illegal, Resumes Issuing Grants Read More »

ARPA-H_RAPID rare disease diagnostics

RAPID Solicitation

Leave a Comment / All Posts, ARPA-H, Life Sciences / By

RAPID_SOL_25_119_FINAL Overview The Advanced Research Projects Agency for Health (ARPA-H) recently announced the newly approved program for Rare disease AI/ML for Precision Integrated Diagnostics (RAPID). The RAPID program aims to significantly improve outcomes for people with rare diseases by reducing diagnostic delays by ≥50%, decreasing misdiagnosis rates, and expanding access to diagnostics. Beyond benefitting the treatment experience of

RAPID Solicitation Read More »

Court Blocks NIH Cap Indirect Cost Rate

Court Blocks NIH Cap on Indirect Cost Rates

Leave a Comment / All Posts, Life Sciences, NIH / By

Court Blocks NIH Cap on Indirect Cost Rates for Government Contracts In a significant development for research institutions and federal contractors, a federal judge has temporarily blocked the National Institutes of Health (NIH) from enforcing its cap on indirect cost rates. This decision comes as a result of a temporary restraining order (TRO) issued by

Court Blocks NIH Cap on Indirect Cost Rates Read More »

NIH Supplemental Guidance

Understanding the NIH Supplemental Guidance on Indirect Cost Rates

Leave a Comment / All Posts, Life Sciences, NIH / By

Overview The National Institutes of Health (NIH) has issued Supplemental Guidance to the 2024 NIH Grants Policy Statement regarding Indirect Cost Rates (NOT-OD-25-068). This update introduces a standardized 15% indirect cost rate for all applicable grants, aiming to streamline financial policies and enhance funding efficiency for research institutions. Purpose of the Guidance The primary objective

Understanding the NIH Supplemental Guidance on Indirect Cost Rates Read More »

US Capitol building silhouette on blue paint texture

Review of Federal Funding: What It Means and What Comes Next for Life Sciences Organizations

Leave a Comment / All Posts, Life Sciences / By

On January 27 and January 28, the Office of Management and Budget (OMB) issued guidance as follows: Memorandum M-25-13, an executive directive halting all federal financial assistance programs as agencies reevaluate spending priorities. An Excel file titled Federal Financial Assistance Program Analysis Template Additional Guidance with Q&A OMB Memorandum M-25-13 Published on January 27, 2025,

Review of Federal Funding: What It Means and What Comes Next for Life Sciences Organizations Read More »

Scroll to Top